REQUEST FOR APPLICATIONS (RFA)

MSCRF Discovery Program

INTRODUCTION:

Stem cell research offers extraordinary promise for new medical therapies and a better understanding of debilitating human diseases, injuries, and conditions. The development of new medical strategies for the prevention, diagnosis, treatment and cure of human diseases, injuries and conditions through human stem cell research is a high priority for the State of Maryland.

FUNDING OBJECTIVES AND PROGRAM OVERVIEW

This Request for Applications (RFA) for Discovery Grant Program is soliciting applications from academic scientists in non-profit research organizations in Maryland who aspire to contribute to the field of stem cell research and regenerative medicine, driving innovative research for improving patient outcomes. is The Discovery grant program supports research directed to new and innovative hypotheses, approaches, mechanisms, or models that differ from current thinking in the stem cell field. Although some preliminary or proof-of-concept data supporting the application is preferred, it is not required. Grants awarded under this RFA will fund both basic and translational research projects involving human stem cells, stem cell derivatives (including extracellular vesicles), or other technologies enabling or supportive of stem cells.

Important note: Revised and improved RFAs.

Funding applications have been modified to include revised and/or new submission fields. Please peruse the recently revised RFAs to be appropriately informed of the changes to prevent delays in the application submission process.

ELIGIBILITY INFORMATION

All MSCRF-funded personnel must conduct their work in Maryland and be employed or retained by an eligible Maryland-based organization while conducting such work. This employment or retainer may be permanent, temporary, full-time or part-time. Applicants from Maryland-based public and private, not-for-profit research organizations of all types (not including Federal research labs) are eligible for this Award (e.g., universities, colleges, research institutes and medical centers).

The applicant may collaborate on the research project proposed in the Application for the Discovery Grant Program ("Research Project") with any Maryland-based institution, including any federal laboratory in Maryland. In the event of a federal laboratory collaboration, a portion of the funds could be allocated to a federal laboratory for carrying out studies outlined in the research project, but the applicant must discuss the nature of collaboration with MSCRF team in advance to ensure that the program requirements are satisfactorily met.

Applicants may submit a Revised Application for a Discovery application that was previously reviewed by the Commission but not funded. Such Proposals must include a point-by-point response to the prior scientific review.

Applicants who have received prior MSCRF funding may apply for a New Award in a subsequent funding cycle on a related or different topic, under the same or a different MSCRF funding mechanism. A summary of the research progress and any publications and/or presentations that resulted from the former MSCRF funding must be included in the Appendix.

Each Application for an Award funded by the MSCRF shall have only one (1) Primary Investigator, but may have multiple Co-PIs, Investigators and/or collaborators. PIs may participate as Investigators or collaborators in any number of MSCRF-funded Projects in the same funding cycle.

Any one candidate may apply to the MSCRF as the PI for only one new Award in any given cycle. Individuals from under-represented minorities and individuals with disabilities are encouraged to apply.

ELIGIBLE RESEARCH AND CELL TYPES:

All research funded by the MSCRF **must** involve human stem cells. Animal cells may be used to supplement studies with human stem cells. Basic and translational research Projects are all eligible for funding. All types of human stem cells, as defined in the Stem Cell Act: The Stem Cell Act defines eligible human stem cells as follows: human cell that has the ability to: (1) divide indefinitely; (2) give rise to many other types of specialized cells; and (3) give rise to new stem cells with identical potential. The full text of the Stem Cell Act is available on the MSCRF Web site (see www.MSCRF.org).

OTHER ELIGIBILITY CRITERIA

Awardees will receive MSCRF funds only after providing documentation to MSCRF confirming that the research to be conducted with MSCRF funds has been approved by the relevant Institutional Review Board ("IRB") and Institutional Animal Care and Use Committee ("IACUC"). Awardees conducting research that involves human pluripotent stem cells must provide documentation of approval by a Stem Cell Research Oversight (SCRO) Committee before MSCRF funds shall be released.

AWARD INFORMATION

AVAILABLE FUNDS

The MSCRF is currently budgeted to commit up to $20.5 million, in aggregate, in FY 2025 to fund Grants under all of its RFAs. The number of Grants awarded will depend upon the quality, size and mix of Applications received.

AWARD SIZE, DURATION & TERMS

Under this RFA, the total amount proposed may not exceed $350,000 per award for a maximum of 2 years duration. Indirect costs may not exceed 15% of the total proposed amount.

Because the nature and scope of the Research Project will vary from Application to Application, the size and duration of Awards may also vary. Approved Research Projects may be funded at or below the requested/proposed amount, for a number or reasons, including potential reductions in State appropriations or funding otherwise available to MSCRF.

MSCRF funds cannot be used to support any Research Project that is or has been funded in its entirety by another funding source. However, an Applicant may receive complementary funding from another source to cover other work that is related to the same overall Research Project.

PI shall assume responsibility for the planning, directing and execution of their proposed Research Project. MSCRF-funded Discovery Research Grants will be subject to the terms and conditions set forth in detail in the Grant Agreement entered into between an Awardee's affiliate institution and TEDCO.

Under this RFA, MSCRF Grant Award funds may be used for the following direct costs, commensurate with the time dedicated solely to the proposed research:

- Salary and fringe benefits for the PI and essential personnel
- Equipment
- Supplies
- Consultant costs
- Contract services
- Collaboration expenses
- Travel and conference expenses (capped at $5000; international travel is not an allowed expense)
- Publications and miscellaneous costs

MSCRF funds may not be used to cover personnel costs of Investigators/collaborators who are located and conduct the work outside the State of Maryland, regardless of whether such out-of-State Investigators/collaborators are employed or retained by a Maryland-based or non-Maryland based organization. Applicants are permitted to include out-of-State investigators and/or collaborators under the Discovery Research Grant if they demonstrate that no MSCRF funds will be used to support work (with the exception of Federal laboratory researchers) or personnel costs for the out-of-State Investigators.

Purchase of equipment and supplies, publication costs, conference expenses, contract manufacturing and services and other non-personnel costs may be incurred outside the State of Maryland, in accordance with customary practices of researchers.

Certain pre-Award costs are allowable. Applicants may, at their own risk, and without the Commission's prior approval, incur obligations and expenditures to cover costs up to ninety (90) days before the beginning date of the initial budget period of the Discovery Research Grant, if such costs are necessary to conduct the Project and would be allowable under the Grant, if awarded.

The incurring of pre-Award costs in anticipation of Award of a Discovery Research Grant imposes no obligation on the Commission either to make the Award, or to increase the amount of the approved budget if an Award is made for less than the amount anticipated. Awardees should be aware that pre-Award costs result in borrowing against future support, and that such borrowing must not impair Awardees' ability to accomplish their Project objectives in the approved time frame or in any way adversely affect the conduct of their Projects.

Once a Grant has been awarded, up to ten (10) percent of funds can be reallocated between budget categories without prior MSCRF approval (e.g., from salaries to supplies). However, reallocations in excess of ten (10) percent must be approved in advance by MSCRF.

INTELLECTUAL PROPERTY

Invention disclosures and intellectual property developed under the Discovery Research Grant funded by the MSCRF will be owned by, and the responsibility of, the recipient PI, in accordance with standard U.S. intellectual property law on inventorship and ownership and the Awardee's affiliate institutional guidelines.

Award recipients shall determine whether to apply for patents or other intellectual property protections on discoveries or inventions developed with MSCRF funding under the Grant. In the event that an Applicant decides to apply for such intellectual property protections, the Applicant shall be responsible for all fees and expenses involved.

SHARING RESEARCH RESULTS AND NEW CELL LINES

Awardees are required to share with qualified researchers their research results and any cell lines and other materials developed with MSCRF funding. Cell lines therefore must be derived from the tissues of individuals who provided consent to such sharing. Awardees may require that the recipient researcher(s) pay reasonable compensation for such new cell lines or materials. Awardees may include in the Grant Budget, and use MSCRF funds to pay for, reasonable expenses associated with sharing arrangements. Awardees shall determine whether and to what extent to cover such sharing of new cell lines and materials with intellectual property and contractual protections (i.e., Confidentiality Agreements, Material Transfer Agreements, Data-Sharing Agreements, License Agreements, Supply Agreements, etc.).

PUBLISHING

Applicants must commit to make the results of their MSCRF-funded research readily available to others, through publications (preferably), public presentations or other accessible means.

APPLICATION AND SUBMISSION INFORMATION

CONTENT & FORMAT OF APPLICATION

All Sections of the Application must be submitted through the MSCRF online submission system. The document must be formatted using point size 12 Arial font with margins no smaller than one-half (0.5) inch on all sides and uploaded in a PDF format using the instructions in the portal. Applications not meeting the minimum requirements will be rejected without further consideration and the Applicant will be so notified.

APPLICATION COMPONENTS

The intent of the Application is to provide enough information so a panel of reviewers can effectively evaluate the merit of the Research Project. Application must include the following information:

Section I. Title of the Research Project

Section II. Web form Questions: Applicant must respond to the following questions:

- New application or resubmission and the prior application number(s) for prior MSCRF applications
- Proposed Research Project period of performance
- The total amount of funding requested, broken down into direct and indirect costs
- Whether the research is translational or basic
- IP status - whether there is a pending or issued patent application (s) directed to the Research Project

- Type of stem cell type that will be used for Research Project
- List the disease indication and disease category for the Research Project
- List Keywords for the Research Project (100 characters limit)
- Short non-confidential summary of the Research Project. If awarded, this information becomes public. Do not include any confidential or proprietary information. (1800 characters limit)
- Public Health Impact Statement: 2-3 sentences on public health impact. If the Research Project outcome will inform the development of a product that serves medically underserved communities or a rare disease, please also specify. (500 characters limit)
- Bioethics statement: describing the ethical issues relevant to the proposed research and how these issues will be addressed, including, but not limited to, a discussion of the ethical issues related to the cell type(s) and cell line(s) to be used; animal welfare (i.e., IACUC); IRB review and related concerns regarding human subjects, if applicable. (1800 characters limit)
- Impact on Biotechnology in Maryland. Describe the potential of this application to impact the biotechnology sector in the state of Maryland. Some examples may include IP that may be licensed or lead to commercialization, existing or proposed collaborations, creation of new jobs, and workforce development. (1800 characters limit)
- Translational Potential and/or Plan: Provide an explanation of (i) the relationship between the proposed research and the etiology, prevention, diagnosis, or treatment of human diseases or conditions; (ii) how clinical practice and treatment of human diseases or conditions will be advanced by the proposed research; (iii) how the proposed research may contribute to new medical therapies or test new therapies in human patients; and/or (iv) how the proposed research will translate prior research results into new medical therapies or test new therapies in human patients, and the projected timeline for accomplishing such clinical application(s) (1800 characters limit)
- PI Areas of scientific expertise (100 characters limit)
- PI Primary research focus (500 characters limit)
- Areas of potential collaboration that the PI is seeking (500 characters limit)
- Indicate the PI's previous experience as an MSCRF applicant and provide the application number if previously funded.
- Enter the URL address of your laboratory.

Section III. People: create records for ALL people associated with your submission. Other than the Institutional Official/Authorized Representative, for every person people record created, a corresponding Biosketch must be included in the Biosketches attachment section of the site. At a minimum, the system requires records for a PI and an Institutional Official/Authorized Representative. **Institutional Official authorization is required for submission.**

Section IV. Attachments: Ensure strict adherence to the page limits. Incompliance with the application requirements will result in disqualification.

A. Research Project Summary - Limited to one (1) page.
Research Project Summary describing the proposed research and its potential contribution toward the goals of the MSCRF and this RFA, as set forth in this document.

B. **Research Plan - Limited to eight (8) pages, including all tables, figures and charts.**
A description of the Research Strategy and Design, Data in support of the Research Project, Significance, Specific Aims, Rationale, Approach and Innovation**.**

C. **Resources and Environment - Limited to one (1) page.**
A description of the facilities in which the work will be conducted and how the scientific environment will contribute to the probability of success, especially such things as independent space, department support and institutional support, collaborative arrangements involving on-site resources.

D. Data Sharing and Management Strategy - Limited to one (1) page.
Facilitating the sharing of data and insights resulting from MSCRF-funded projects is pivotal for propelling stem cell research and expediting patient treatments. MSCRF mandates awardees to create and implement a comprehensive Data Sharing and Management Strategy encompassing data handling, preservation, and accessible dissemination to the wider scientific community. Moreover, MSCRF enforces adherence to FAIR data principles and necessitates data sharing via recognized repositories like specialized NIH-supported repositories, generalist repositories, cloud platforms, and institutional repositories.

E. Resubmissions - Limited to two (2) pages.
In the event that an Applicant PI's proposal is initially rejected, and the Applicant PI chooses to reapply for Program funding, the Applicant PI must submit a written response to the reviewers' comments including how those comments were addressed in the resubmitted application. Please include an introduction to the revised Application, including the Application Number of the previous MSCRF submission, and a point-by-point response to the prior scientific review.

6. Collaboration Plan, if applicable - Limited to two (2) pages.
A detailed description of the nature and terms of the collaboration, and a management plan explaining such issues as how the Applicant PI and collaborator(s) will communicate and handle confidential information, use milestones to determine resource allocation and Research Project direction, share data and resources, prepare required reports and handle geographic separation, if applicable.

7. Supporting Literature - Limited to two (2) pages.
Provide a list of scientific Literature in support of the Research Project.

8. Biosketches: Do not exceed five (5) pages for the PI/Co-PI and two (2) pages each for other key project personnel.

9. Other Support: List Other Support for the PI, including both current and pending support as described in the instructions.

10. DEI Registration: Pursuant to its enabling legislation, TEDCO is required to foster inclusive and diverse entrepreneurship and innovation throughout Maryland. Accordingly, TEDCO is now collecting race, gender, and ethnicity data, to better understand the communities that are accessing MSCRF resources/funding. This data will not be accessible to MSCRF/TEDCO program/fund managers and will only be provided to them in an aggregated (anonymous) form. The data will not be used for funding consideration.

11. Budget and Budget Justification: A list of the names, affiliate organizations, and roles of all key personnel, in addition to the Applicant PI, who will contribute to the scientific development or

execution of the Research Project in a substantive way and devote measurable effort (in person months) to the Research Project, whether or not salaries are requested. Typically, these individuals have doctoral or other professional degrees, although individuals at the master's or baccalaureate level should be included if their involvement meets the definition of key personnel. "Effort of zero person months" and "as needed" are not acceptable levels of involvement for key personnel.

Up to 15% of Discovery awards may be used for indirect costs. Expenses for domestic travel are capped at $5000. International travel is not an allowable expense.

All expenses directed to the Research Project should adhere to the specific line items listed in the proposal. Any budget changes or reallocation of funds between budget categories over 10% of the overall budget must be approved by MSCRF **prior to** reallocation. In the event of remaining unspent funds from one installment, a carryover request must be submitted to MSCRF for approval to carry the funds to the next installment with a justification of why the funds were not used and how they will be used in the next installment.

MSCRF funds may not be used to cover personnel costs of Investigators who are located and/or conduct the work outside the State of Maryland, regardless of whether such out-of-State Investigators are employed or retained by a Maryland-based or non-Maryland based organization. Applicants are permitted to include out-of-State Investigators and/or collaborators under the Commercialization Research Grant if they demonstrate that no MSCRF funds will be used to support work or personnel costs for the out-of-State Investigators.

12. **Appendix - Collaborator Letters:** The PI should include Letters of Collaboration, if applicable. A Letter of collaboration from each collaborator on university, institute, or company letterhead (i) agreeing to the proposed collaborative research; (ii) briefly outlining the nature of the collaboration; and (iii) agreeing that, if MSCRF funding is awarded, they shall share research results with each other and comply with the progress reporting duties under the MSCRF Grant Agreement, conditioned upon TEDCO's duty to maintain the confidentiality of the reported information to the extent reasonably permitted by Title 10, Subtitle 6 of the State Government Article of the Annotated Code of Maryland. Such letters must be co-signed by the collaborators and responsible officials at the collaborator's affiliate institutions. Limited to one (1) page per Collaborator.

13. **Appendix - Summary of Prior Research Progress, if Applicable - Limited to two (2) pages.**
For Applicants who have had previous MSCRF funding and are requesting funding for a New MSCRF Award: The Summary of the research progress and/or findings from the previously funded MSCRF Project, including a list of any publications, new collaborations, INDs, IDEs or patents, and any additional non-MSCRF funding that resulted from this previous MSCRF funding.

14. **Appendix – Supporting Materials:** This section may not be used to circumvent the length limitations of the Application. Do not include information that should be in the main proposal application. Complete the checklist template on the portal to list the documents included in this section. **Compile all supporting documents into a single PDF file.**

15. **Photo:** Upload a headshot photo of the PI for publishing on the MSCRF website if awarded.

Notes:

- The Appendix may not be used to circumvent the length limitations of the Application. Applications that are incomplete, do not meet the format and/or content requirements, exceed specified length limits, are non-responsive to this RFA or are from ineligible Applicants will not be reviewed.
- University Applicant PIs must obtain approval from their research/grants administration office before submitting an application.

SUBMISSION DEADLINES & REVIEW DATES

- **Application submission deadline:** January 13, 2025, by 12:00 p.m. EST.
- **Peer review date(s):** Week of March 17, 2025
- **Commission review date(s) and announcement of awards:** May 2025

METHODS OF SUBMISSION

Principal Investigators are encouraged to register in the MSCRF online submission system at least one month before the Application Submission Deadline. Grant Applications must be submitted through the MSCRF online submission system by January 13, 2025, no later than 12:00 p.m. **Late submissions will not be considered.**

REVIEW INFORMATION

ELIGIBILITY AND COMPLIANCE REVIEW:

All applications will be initially reviewed by the MSCRF staff to ensure that they meet the minimum requirements, as specified in this RFA (the "Compliance Review"). Applications not meeting the minimum requirements will be rejected without further consideration and the applicant will be so notified. A complete submission (all sections) cannot exceed the page limit as included for each section or it will be rejected without consideration.

REVIEW PROCESS:

Following the Eligibility and Compliance Review, all Applications will be assigned by the MSCRF Scientific Review Officer (SRO) to a number of reviewers for review and preliminary scoring. All Applications, receiving average scores above a threshold determined by the Program will be brought to the full MSCRF Review Committee.

The MSCRF Review Committee will consist of representatives of the research, business and investor community and are all from outside of the state of Maryland. Each applicant will receive a copy of the reviewer comments and scores at the end of the process, whether the applicant is approved or declined for funding.

REVIEW CRITERIA:

Applicants will be evaluated on each section of their proposal listed under the application components and the applicant's ability to address each criterion listed in those sections. **Consideration will be based on how completely the applicant has provided information requested for the section and how convincingly the applicant has made a case for the opportunity based on the subject Technology.**

To receive a high impact/priority score, Applicants are encouraged to address the following categories:

- **Meeting the Overall Objectives of The MSCRF Program:** Do the proposed studies broaden and advance the knowledge of human stem cell biology? Are they relevant to the development of commercial and or clinical application(s) to prevent, diagnose and treat human diseases and conditions? Will these studies enable, support and expedite such commercial and or clinical applications?

- **Relevance to Regenerative Medicine:** Does the proposed research use adult, embryonic, iPS or other human stem cell lines? Does the PI justify the use of human stem cells in the proposed research as necessary or advantageous as compared to other approaches? Does the Project address problems in regenerative medicine, as defined by the Commission?

- **Likelihood of Success:** Are there limitations of the proposed studies that will make it difficult to apply findings or strategies in the clinic? Are there completed or on-going clinical trials that will impede/accelerate the proposed research?

- **Translation Potential and Plan**: Does the Application include strong interactions between basic, translational and/or clinical components? Is there a clear plan for translating research results to the clinic? Will the Project lead to new medical therapies or test new therapies in patients? Will the research help explain the course of any human disease(s) or condition(s)? Will it identify new biomarkers or other methods for preventing or diagnosing disease(s) or condition(s)? Will it identify new targets for treatment? Will it develop new treatment strategies, products or tools?

- **Collaboration(s):** Does the proposed research involve collaboration(s) among scientists and/or clinicians from for-profit and not-for-profit institutions, companies and organizations? If so, is there a demonstrated commitment from each institution? Is there a management plan that addresses how the Applicant and collaborator(s) will communicate, handle confidential information, use milestones to determine resource re-allocation and Project re-direction, share data and resources, prepare required reports and handle geographic separation, if applicable?

- **Scientific Merit:** Is the Project likely to have major scientific impact and make a substantial contribution toward accomplishing the goals of the MSCRF program?

- **Research Significance:** Does this Project address an important scientific problem, relevant to human stem cells? What is the relationship between the proposed research and the etiology, prevention, diagnosis or treatment of human diseases or conditions? If the aims of the Application are achieved, how will scientific knowledge or clinical practice and treatment of human diseases or conditions be advanced? What effect will these studies have on the concepts, methods, technologies, treatments, services and/or preventative interventions that drive stem cell biology?

- **Innovation:** Is the Project original and innovative? Does it challenge existing paradigms or clinical practice or address a novel hypothesis or critical barrier to progress in the field? Does it develop or employ new concepts, approaches, methodologies, tools or technologies in the field? What is the potential impact on the advancement of biotechnology or medical innovation?

- **Approach:** Is there adequate preliminary data to support the rationale of the Research Project? Are the conceptual or framework, design, methods and analyses adequately developed, well integrated,

well-reasoned and appropriate to the aims of the Project? Is relevant literature appropriately referenced? Are anticipated results discussed? Does the Applicant acknowledge potential problem areas and consider alternative tactics? Are the experiments as designed likely to significantly impact the field?

- **Investigators:** Are the Investigators appropriately trained and well suited to carry out the Project? Is the proposed Project appropriate to the experience level of the PI and other Investigators? Does the research team bring complementary and integrated expertise to the Project?

- **Budget and Budget Justification:** Is the requested period of support appropriate for the scope of the Project? Is the effort listed for all personnel appropriate for the proposed work? Is each budget category realistic and justified in terms of the aims and methodology? If equipment is requested, is it justified, cost effective and budgeted appropriately?

- **Resources and Environment:** Does the scientific environment in which the work will be conducted contribute to the probability of success? Do the proposed studies benefit from any unique features of the scientific environment or subject population? Do these studies employ useful collaborative arrangements involving on-site resources or personnel? Is the institutional support adequate?

- **Bioethics:** Does the proposed research use adult, embryonic, iPS or other human stem cell lines? If an existing line is to be used, what are the justifications for that line? If new lines are to be created, what measures will be taken to comply with the Stem Cell Act as well as existing stem cell research bioethics guidelines? If human donors are involved, have they been properly consented? If human subjects are involved, what protections will be in place to ensure their rights and welfare? If animal subjects are to be used, what measures are taken to comply with IACUC guidelines?

If the PI's work was previously funded by the MSCRF, in whole or in part, the Application will be evaluated on the following additional factors: Did the Investigator make significant scientific progress towards the goals of the previously funded research? Were results of the previously funded Project reported in scientific publications and/or presented at conferences? Did the previously funded research result in new collaborations, inventions or Project-generated resources as proposed in the original Application? Did the previous Project generate subsequent funding from non-MSCRF sources?

The Commission reserves the right to pursue collaborative funding arrangements with third parties and, in such an event, the further right to share the application materials and/or the review summaries with those potential co-funders upon the execution of a Confidentiality Agreement restricting their further disclosure.

SCORING

The Scientific Peer Review Committee will review all Applications and rank them. Similar to the NIH scoring system of 1-9 will be used to rate the overall impact/priority of the proposed research. In this system, “1” indicates the highest impact/priority and “9” indicates the lowest impact/priority. The Commission will then review the ranked Applications and make final funding decisions.

AWARD ADMINISTRATION INFORMATION

NOTIFICATION

The PI's affiliate organization will be notified electronically when the Application is received. A formal notification, in the form of a Notice of Award ("NOA"), signed by the MSCRF Executive Director, will be sent via email to successful Applicants.

POST AWARD REPORTING

Discovery Program awardees must submit the following reports to the MSCRF Program:

a. **MSCRF Award Meeting** – Each applicant is required to meet with the MSCRF Award Manager at least once, prior to the mid-term. This is to assist each awardee in understanding and meeting expectations for the program. This is also an opportunity for the awardee to share feedback, discuss ideas and ask for additional assistance. The applicant can reach out to MSCRF staff at mscrfinfo@tedcomd.com email to schedule this meeting.

b. **Mid-Term Project Reports** – Each applicant is required to submit the mid-term project report ("progress report") on MSCRF portal, the link to which will be provided in advance of the submission date by MSCRF. The progress report must include a description of project activities and outcomes to date, progress toward meeting mid-term milestones, an accounting of expenditures charged to the award, and information on any deliverables, such as products, public presentations, publications, intellectual property, and follow-on funding. The progress report template is available upon request from MSCRF staff at any time. This step is required before the report is approved and the remaining award payment disbursement is made.

c. **Final Reports -** Each applicant is required to submit the final report on MSCRF portal, the link to which will be provided in advance of the submission date by MSCRF. A final report must provide an overview of all activities undertaking during the course of the funded project, a description of the results of the project, the success with achieving the proposed milestones, jobs created/supported, information on any deliverables, such as products, public presentations, publications, intellectual property, and follow-on funding, as well as a full accounting of all expenditures charged to the award in a tabular format signed by the financial officer, and a formal closeout letter. The final report template is available upon request from MSCRF staff at any time.

d. **Symposium presentation** - The MSCRF may conduct an in-State Annual Symposium to report to the scientific community and the public on the progress of the MSCRF program. All PIs must present, orally or in poster format, their on-going or completed MSCRF-funded research at each Annual Symposium, during and immediately following their Grant period.

COMPLIANCE

A Principal Investigator not in compliance with the reporting obligations under the Discovery Research Grant shall not be eligible to apply for continued or subsequent MSCRF funding.

AGENCY CONTACTS

- Inquiries about this RFA or other programmatic matters should be submitted by email to: mscrfinfo@tedcomd.com

- Inquiries regarding technical assistance with the application and/or reporting portal should be submitted by email to: mscrf@aibs.org